Edition:
India

Profile: Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

1.79USD
8:23pm IST
Change (% chg)

$-0.07 (-3.76%)
Prev Close
$1.86
Open
$1.86
Day's High
$1.86
Day's Low
$1.76
Volume
19,284
Avg. Vol
128,082
52-wk High
$8.30
52-wk Low
$1.70

Aduro Biotech, Inc., incorporated on May 5, 2011, is an immunotherapy company. The Company focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes (STING) Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies (i.e. chemotherapy and radiation), as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian, and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively. A personalized form of LADD (pLADD) is being developed utilizing tumor neoantigens that are specific to an individual patient's tumor.

The STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is a STING Pathway Activator compound to enter the clinic and is being evaluated in a Phase I study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Its B-select monoclonal antibody platform includes an ultra-selective functional screening process to identify antibodies with binding properties against a range of targets that are being designed to modulate the innate and adaptive arms of the immune system. The B-select platform has delivered various immune modulating assets in research and preclinical development. It is developing a pipeline of product candidates on its own and have a number of collaborations with global pharmaceutical companies to expand its products and technology platforms.

The Company has developed LADD product candidates in collaboration with Janssen Biotech, Inc. targeting lung and prostate cancers and it is developing STING Activator product candidates in oncology under its worldwide collaboration with Novartis Pharmaceuticals Corporation. In addition, it is developing monoclonal antibodies (mAbs) with the potential to yield immunotherapy combinations through its subsidiary, Aduro Biotech Holdings, Europe B.V., known as Aduro Biotech Europe, based in the Netherlands. It is using CRS-207 in combination with standard-of-care chemotherapy for treatment in the front line-setting of unresectable malignant pleural mesothelioma. It has completed two Phase II trials in pancreatic cancer with CRS-207 and GVAX Pancreas.

ADU-214 is a bivalent LADD product candidate expressing EGFRvIII and mesothelin. It has initiated Phase I study, which evaluates intravenous administration of ADU-214 in patients with advanced or metastatic non-small cell lung cancer. ADU-741 is a LADD product candidate engineered to express multiple antigens. It has initiated the Phase I trial, which evaluates intravenous administration of ADU-741 in patients with metastatic castration resistant prostate cancer. Its STING Pathway Activator product candidate, ADU-S100, with modifications to the mammalian cyclic dinucleotide (CDN) structure is designed to optimize stability, STING receptor binding affinity and potency. Its anti- A PRoliferation-Inducing Ligand (APRIL) antibody is its B-select mAb, which is being developed as a therapy for multiple myeloma. CD27 is a co-stimulatory receptor expressed on different immune cells, such as T-lymphocytes and natural killer (NK) cells. Programmed cell death protein 1 (PD-1) is expressed on the surface of activated T cells, B cells and dendritic cells. Its CTLA-4 antibody is being advanced through pre-clinical development and it is conducting IND-enabling studies.

The Company competes with AstraZeneca PLC, Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., Roche Holding Ltd, Sanofi SA, Advaxis, Inc., Merck & Co., Inc. and Visterra, Inc.

Company Address

Aduro Biotech Inc

740 Heinz Ave
BERKELEY   CA   94710-2748
P: +1510.8484400
F: +1302.6555049

Company Web Links